LOW-VOLUME · SEX-BALANCED

nalbuphine Side Effects

nalbuphine (also sold as Nubain) is a LOW-VOLUME FAERS extract #515 of 524 by FAERS report count. Still opens on SEX-BALANCED: 69% of sex-coded reports are female (135 F / 62 M).

Data updated 2026-05-15

218
FAERS reports

Thinner FAERS book - still a temporal association ledger, not proof of cause. Methodology.

nalbuphine reporting skew - 69% of sex-coded reports are female (135 F / 62 M). Volume band LOW-VOLUME #515 of 524 by FAERS report count; caseload TRACE-CASE.

Thinner FAERS extract for nalbuphine (Nubain) (218 reports #515 of 524 by FAERS report count). 69% of sex-coded reports are female (135 F / 62 M). Sparse books still carry named reaction rows when present; not medical advice.

Counts from the openFDA FAERS extract (2007–2025). Stamps TRACE-CASE · DEATH-MARKED · HOSP-HEAVY · SEX-BALANCED.

DRUG HYPERSENSITIVITY leads 36 of 218 reports

DRUG HYPERSENSITIVITY
36
FOETAL EXPOSURE DURING PREGNANCY
10
NEONATAL ASPHYXIA
10
NEONATAL EPILEPTIC SEIZURE
10
PAIN
7
PANCREATITIS ACUTE
7
ACUTE HEPATIC FAILURE
6
ENCEPHALOPATHY
6
PRODUCT PACKAGE ASSOCIATED INJURY
6
PRURITUS
6
PYREXIA
6
DRUG INTERACTION
5
FATIGUE
5
HEADACHE
5
HYPERTENSION
5
MALAISE
5
NAUSEA
5

Who reports · age peak 0-17 (SEX-BALANCED)

Sex coding · SEX-BALANCED

Female 135 (69%)
Male 62 (31%)

Age peak 0-17 (74 reports)

0-17 74 (45%)
18-44 28 (17%)
45-64 30 (18%)
65-74 19 (12%)
75+ 12 (7%)

FAERS filings rising toward 2025

2007 2025

Reactions in Death Reports

Death appears on 10 reports (4.6% - MARKED). Reactions below co-occur in those rows only.

Reaction Reports
ACUTE KIDNEY INJURY 2
CONTUSION 2
HYPERTENSION 2
HYPOTENSION 2
RENAL IMPAIRMENT 2
RESPIRATORY FAILURE 2
ANAEMIA 1
ANAPHYLACTOID REACTION 1
AREFLEXIA 1
B-CELL TYPE ACUTE LEUKAEMIA 1
BACK PAIN 1
BLINDNESS UNILATERAL 1
BLISTER 1
BRAIN MIDLINE SHIFT 1
BRAIN OEDEMA 1
CANDIDA SEPSIS 1
CAPILLARY LEAK SYNDROME 1
CARDIO-RESPIRATORY ARREST 1
CEREBRAL HAEMORRHAGE 1
CHRONIC KIDNEY DISEASE 1

Reactions in Hospitalization Reports

Hospitalization is HEAVY (77, 35.3% of the book). Top reactions in those rows:

Reaction Reports
ACUTE HEPATIC FAILURE 6
PANCREATITIS ACUTE 6
FEBRILE BONE MARROW APLASIA 4
MENTAL STATUS CHANGES 4
PYREXIA 4
CARDIAC PERFUSION DEFECT 3
DRUG CLEARANCE DECREASED 3
FATIGUE 3
HAEMODYNAMIC INSTABILITY 3
INTRA-ABDOMINAL HAEMORRHAGE 3
RESPIRATORY FAILURE 3
ACUTE KIDNEY INJURY 2
AGRANULOCYTOSIS 2
AMNESIA 2
ANAEMIA 2
ASPARTATE AMINOTRANSFERASE INCREASED 2
ASTHENIA 2
BRADYCARDIA 2
How to read nalbuphine FAERS figures (TRACE-CASE · DEATH-MARKED · HOSP-HEAVY)

FAERS holds 218 voluntary reports linked to nalbuphine (Nubain), 2007-2025. Death is listed on 10 (4.6%). Hospitalization appears on 77 (35.3%). Top co-reported indication: Product Used For Unknown Indication.

Sparse extract - named reactions and SEX-BALANCED skew still differ by drug; not a complete safety profile.

Read with nalbuphine

Peers ranked by ABS(total_reports), then an ABS(death_share) pole; guide hop follows DEATH-MARKED · HOSP-HEAVY stamps.